Boehringer Ingelheim closes in on full ownership of SSP
This article was originally published in Scrip
Boehringer Ingelheim has moved a step closer to fully acquiring its already majority-held Japanese affiliate, SSP, following the completion of a successful tender offer.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.